Showing results (171-180 of 322) with videos related to

Sort By:
Pageof 33
The Lancet. Haematology|December 25, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialClaire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, et al.
American Journal of Hematology|July 8, 2017
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemiaHans Michael Kvasnicka, Attilio Orazi, Juergen Thiele, et al.
Blood Cancer Journal|December 9, 2017
CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profilesRoberta Zini, Paola Guglielmelli, Daniela Pietra, et al.
Cancers|August 14, 2025
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome PredictionIrene Attucci, Benedetta Peruzzi, Chiara Nozzoli, et al.
Plos One|December 15, 2010
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosisVittorio Rosti, Elisa Bonetti, Gaetano Bergamaschi, et al.
Blood|December 17, 2009
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasmPhilip A Beer, François Delhommeau, Jean-Pierre LeCouédic, et al.
Blood|March 13, 2009
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceGiovanni Barosi, Gunnar Birgegard, Guido Finazzi, et al.
Stem Cells and Development|December 21, 2017
Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic DifferentiationSimona Salati, Zelia Prudente, Elena Genovese, et al.
Haematologica|April 9, 2026
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequencyPaola Guglielmelli, Chiara Paoli, Giulia Borgi, et al.
Journal of Hematology & Oncology|October 1, 2017
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analysesSrdan Verstovsek, Jason Gotlib, Ruben A Mesa, et al.
Pageof 33